U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07268937) titled 'Assessment of Hepatic Steatosis Using Dedicated Software Implemented on Ultrasound Devices' on Nov. 25.
Brief Summary: Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, with an estimated prevalence of 5-30% in the general population and 55-80% in patients with type 2 diabetes.
Methods for the quantitative and non-invasive assessment of liver fat content have recently been implemented on ultrasound devices, based on the estimation of the ultrasound beam attenuation coefficient and backscattering. These methods are CE marked and already commercially available.
The aim of the study is to com...